Executive Director of Market Access & HEOR

Company Overview

Immunome is a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted therapies designed to improve outcomes for cancer patients. We are advancing an innovative portfolio of therapeutics, drawing on leadership that previously played key roles in the design, development, and commercialization of cutting-edge targeted cancer therapies, including antibody-drug conjugate therapies (ADCs). Our most advanced pipeline programs are varegacestat (formerly AL102), a gamma secretase inhibitor which is currently in a Phase 3 trial for treatment of desmoid tumors; IM-1021, a ROR1-targeted ADC which is currently in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand, which recently received IND clearance. Our pipeline also includes IM-1617, IM-1335, and IM-1340, all of which are preclinical ADCs pursuing undisclosed targets with expression in multiple solid tumors.

Position Overview

Immunome is preparing for the global launch of varegacestat, its first commercial therapy. To ensure strong access and reimbursement across markets, we are seeking an accomplished and strategic Executive Director of Market Access & HEOR to lead our value, evidence, and access strategy for the therapy.

This leader will serve as the architect of the value proposition for varegacestat—designing and executing the evidence generation, economic modeling, payer strategy, and global value materials needed to secure favorable coverage decisions. The role will oversee U.S. and ex-U.S. access strategy, lead development of the Budget Impact Model (BIM) and Global Value Dossier (GVD), and be responsible for the Joint Clinical Assessment (JCA) required under Europe’s new HTA regulation.

The ideal candidate combines deep HEOR expertise with hands-on experience preparing innovative oncology therapies for launch in complex reimbursement environments.

Responsibilities

Market Access Leadership

• Lead U.S. and global market access strategy for varegacestat to enable favorable payer coverage, formulary placement, and patient affordability.
• Shape payer-focused value messaging, ensuring clinical and economic evidence aligns with the needs of commercial, Medicare, and Medicaid payers.
• Conduct payer landscaping, contracting evaluations, and access scenario analysis to guide launch decisions.

Value Demonstration & HEOR Strategy

• Design and implement the HEOR strategy supporting early and long-term access, including evidence gap assessments, real-world evidence (RWE) planning, burden of illness, QoL, and comparative effectiveness studies
• Lead creation of all global value communication tools, including the Global Value Dossier, AMCP dossier, value narratives, and payer objection handling resources.
• Translate clinical, humanistic, and economic evidence into compelling, differentiated payer value stories.

Economic Modeling & Analytics

• Oversee development of the Budget Impact Model (BIM) and Cost-Effectiveness Model (CEM) to support payer engagements, HTA submissions, and pricing strategy.
• Ensure models reflect real-world clinical pathways, distribution nuances, and relevant cost drivers across markets.
• Guide adaptation of economic models for different geographies and payer archetypes.

Global Regulatory & HTA Strategy

• Serve as the commercial lead for the Joint Clinical Assessment (JCA) for Europe, ensuring all clinical and economic evidence requirements are met.
• Partner with regulatory, medical, and global market access partners to navigate emerging EU HTA guidelines and country-specific requirements.
• Guide development of country-level HTA submissions (e.g., G-BA, HAS, AIFA, NICE, CADTH) in alignment with global strategy.

Cross-Functional & Launch Leadership

• Partner closely with Clinical Development, Medical Affairs, Regulatory, Biostatistics, and Commercial to ensure evidence generation aligns with payer needs.
• Lead cross-functional HTA and access readiness teams to ensure alignment on pricing, evidence, and reimbursement strategy.
• Provide payer insights to inform TPP refinement, label strategy, forecasting, and life cycle management plans.
• Support international teams on price corridor design and global launch sequencing.

Engagement & External Leadership

• Prepare and support engagement with U.S. payers, PBMs, IDNs, and oncology networks.
• Represent HEOR/Market Access in KOL engagements, advisory boards, and payer-facing discussions.
• Oversee development of payer education materials and evidence presentations.

Qualifications

• Bachelor’s degree required; advanced degree (MPH, MS, PharmD, PhD, MBA with HEOR concentration) strongly preferred.
• A minimum of 12 years of experience in Market Access, HEOR, or related functions within biopharma, with a strong track record in oncology.

Knowledge and Skills

• Demonstrated leadership in developing HEOR evidence strategies, BIMs, CEMs, and global value dossiers.
• Direct experience preparing AMCP dossiers, HTA submissions, and leading global value and pricing strategy.
• Experience with the EU Joint Clinical Assessment (JCA) or country-level HTA processes required or strongly preferred.
• Strong understanding of payer systems, reimbursement dynamics, and oncology care pathways in both U.S. and global markets.
• Proven ability to collaborate across clinical, medical, regulatory, and commercial functions in a high-growth biotech environment.
• Excellent communication skills with the ability to translate complex data into persuasive payer-ready insights.

E/E/O

Immunome, Inc. is an equal opportunity employer. We celebrate diversity and are committed to creating an inclusive environment for all employees.

E-Verify

Immunome, Inc. is a participant in E-Verify. Please review the following notices: E-Verify Participation Poster | Right to Work Poster (English) | Right to Work Poster (Spanish).